<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02328469</url>
  </required_header>
  <id_info>
    <org_study_id>mgt-0614</org_study_id>
    <nct_id>NCT02328469</nct_id>
  </id_info>
  <brief_title>Aseptic Meningoencephalitis in Slovenia</brief_title>
  <official_title>Prospective Study of the Etiology, Pathogenesis, Clinical Picture and Outcome of Aseptic Meningitis in Slovenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Slovenian Research Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ljubljana School of Medicine, Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is:

        -  to establish etiology of acute aseptic meningitis/meningoencephalitis in Slovenia

        -  to assess the clinical course and outcome of tick-borne encephalitis and Lyme
           neuroborreliosis

        -  to characterize the inflammatory proteins, gene polymorphisms, and transcriptome
           profiles in patients with tick-borne encephalitis and Lyme neuroborreliosis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in selected clinical parameters in patients with acute aseptic meningitis/meningoencephalitis</measure>
    <time_frame>at enrollment and during 12 months follow-up</time_frame>
    <description>Selected clinical parameters (presence or absence of headache, nausea, vomiting, neurologic symptoms, maximal temperature, etc) in aseptic meningitis/meningoencephalitis patients at enrollment (at admission to hospital) and at follow-up visits: on day 7 or on day of discharge from hospital, on day 14, at 2, 6, and 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in selected laboratory parameters in patients with acute aseptic meningitis/meningoencephalitis</measure>
    <time_frame>at enrollment and during 12 months follow-up</time_frame>
    <description>Selected laboratory parameters (complete blood count, biochemistry test results) in aseptic meningitis/meningoencephalitis patients at enrollment (at admission to hospital) and at follow-up visits: on day 7 or on day of discharge from hospital, on day 14, at 2, 6, and 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in selected microbiologic parameters in patients with acute aseptic meningitis/meningoencephalitis</measure>
    <time_frame>at enrollment and during 12 months follow-up</time_frame>
    <description>Selected microbiologic parameters (anti Borrelia burgdorferi immunoglobulin M and G in serum and cerebrospinal fluid results, polymerase chain reaction for enteroviruses, herpes simplex virus type 1 and 2 in cerebrospinal fluid results) in aseptic meningitis/meningoencephalitis patients at enrollment (at admission to hospital) and anti Borrelia burgdorferi immunoglobulin M and G in serum at follow-up visits: at 2, 6, and 12 months.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Aseptic Meningitis</condition>
  <arm_group>
    <arm_group_label>unidentified aseptic meningitis</arm_group_label>
    <description>Patients with etiologically unidentified aseptic meningitis will be treated with symptomatic therapy and will be asked to complete a questionnaire.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tick-borne encephalitis</arm_group_label>
    <description>Patient with aseptic meningitis in whom serological diagnosis of tick-borne encephalitis will be established. Patients will be treated with symptomatic therapy and will be asked to complete a questionnaire.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lyme neuroborreliosis</arm_group_label>
    <description>Patients with acute aseptic meningitis in whom Lyme neuroborreliosis will be proven or suspected according to microbiological criteria. Patients will be treated with antibiotic therapy (ceftriaxone or doxycycline) and will be asked to complete a questionnaire.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <description>Patients will be asked to refer a spouse to serve as a control . If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>identified aseptic meningitis</arm_group_label>
    <description>Patients with microbiologically identified cause of acute aseptic meningitis/meningoencephalitis will receive symptomatic therapy. If the identified causative agent will be Herpes Simplex Virus or Varicella Zoster Virus, patients will be treated with acyclovir and will be asked to complete a questionnaire.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>symptomatic therapy</intervention_name>
    <description>patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline</description>
    <arm_group_label>unidentified aseptic meningitis</arm_group_label>
    <arm_group_label>tick-borne encephalitis</arm_group_label>
    <arm_group_label>Lyme neuroborreliosis</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>identified aseptic meningitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone or Doxycycline</intervention_name>
    <description>beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days</description>
    <arm_group_label>Lyme neuroborreliosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire</intervention_name>
    <description>Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.</description>
    <arm_group_label>unidentified aseptic meningitis</arm_group_label>
    <arm_group_label>tick-borne encephalitis</arm_group_label>
    <arm_group_label>Lyme neuroborreliosis</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>identified aseptic meningitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir</intervention_name>
    <description>Patients will be treated with intravenous acyclovir 10 mg per kg three times daily for 14 to 21 days.</description>
    <arm_group_label>identified aseptic meningitis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples of full blood, serum and plasma will be collected and retained in deep freezer for
      further analyses.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        adult patients with acute aseptic meningitis/meningoencephalitis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical picture compatible with aseptic meningitis/meningoencephalitis

          -  age 18 years or older

          -  clear cerebrospinal fluid on macroscopic examination

          -  cerebrospinal pleocytosis (&gt; 5 x 106 white blood cells per liter)

        Exclusion Criteria:

          -  younger than 18 years

          -  pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franc Strle, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Ljubljana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daša Stupica, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Ljubljana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daša Stupica, MD, PhD</last_name>
    <phone>+386 1 5222110</phone>
    <email>dasa.stupica@kclj.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franc Strle, MD, PhD</last_name>
    <phone>+386 1 5222610</phone>
    <email>franc.strle@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia</name>
      <address>
        <city>Ljubljana</city>
        <zip>1525</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daša Stupica, MD</last_name>
      <phone>+386 1 522 2110</phone>
      <email>dasa.stupica@kclj.si</email>
    </contact>
    <contact_backup>
      <last_name>Franc Strle, MD</last_name>
      <phone>+386 1 5222610</phone>
      <email>franc.strle@kclj.si</email>
    </contact_backup>
    <investigator>
      <last_name>Daša Stupica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franc Strle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Ljubljana, Department of Infectious Diseases</name>
      <address>
        <city>Ljubljana</city>
        <zip>1525</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daša Stupica, MD, PhD</last_name>
      <phone>+386 1 522 2110</phone>
      <email>dasa.stupica@kclj.si</email>
    </contact>
    <contact_backup>
      <last_name>Franc Strle, MD, PhD</last_name>
      <phone>+386 1 522 2610</phone>
      <email>franc.strle@kclj.si</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>December 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Franc Strle</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>aseptic meningitis</keyword>
  <keyword>tick-borne encephalitis</keyword>
  <keyword>Lyme neuroborreliosis</keyword>
  <keyword>inflammation</keyword>
  <keyword>outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Aseptic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
    <mesh_term>Thiethylperazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

